Bristol-Myers Squibb & Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for P...
September 22 2014 - 08:00AM
Business Wire
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE:
PFE) today announced charitable donations totaling more than $1
million to be granted between 2014 and 2016 to seven nonprofit
organizations that support patients with cardiovascular disease.
The donations will fund the independent development of innovative
educational materials about stroke risk reduction in patients with
nonvalvular atrial fibrillation (NVAF). The materials, accessible
to both patients and caregivers, will address disease awareness,
identification of signs and symptoms, access to care, appropriate
treatment options, shared decision making and medication adherence.
National Stroke Association, Heart Rhythm Society, American College
of Physicians, American Heart Association Founders Affiliate,
Regents of the University of Michigan/Society for Vascular
Medicine, WomenHeart and American College of Emergency Physicians
will each receive a charitable donation to support their
independent educational initiatives.
“Bristol-Myers Squibb and Pfizer are committed to helping
patients living with NVAF better understand their increased risk
for stroke and how to take action to appropriately manage this
risk,” said Christoph Koenen, vice president, U.S. Medical,
Cardiovascular, Bristol-Myers Squibb. “We are proud to support
these organizations in their efforts to help educate and empower
patients and caregivers.”
Atrial fibrillation (AF) is the most common type of irregular
heartbeat. It is estimated that more than 5.8 million Americans
have AF. One of the most serious medical concerns for individuals
with AF is the increased risk of stroke, which is five times higher
in people with NVAF than in those without it. In North America it
is estimated that 98 percent of patients with AF have NVAF. NVAF is
a type of AF that is not due to rheumatic mitral heart valve
disease, a prosthetic heart valve, or a repairing of the heart’s
mitral valve.
“These seven nonprofit organizations were chosen because they do
essential work each and every day to connect with patients and they
are critical in continuing to raise awareness of devastating
cardiovascular diseases,” said Brian Klee, group lead, U.S. Medical
Affairs, Cardiovascular, Pfizer. “The Bristol-Myers Squibb/Pfizer
Alliance is honored to be able to support these organizations in
providing innovative, educational resources to both patients and
caregivers.”
Visit the recipient websites to learn more about these
organizations:
- National Stroke Organization:
www.stroke.org
- Heart Rhythm Society:
www.hrsonline.org
- American College of Physicians:
www.acponline.org
- American Heart Association:
www.heart.org
- Regents of the University of Michigan:
www.regents.umich.edu
- WomenHeart: www.womenheart.org
- American College of Emergency
Physicians: www.acep.org
About the Bristol-Myers Squibb/Pfizer Alliance
In 2007, Pfizer and Bristol-Myers Squibb entered into a
worldwide collaboration to develop and commercialize apixaban, an
oral anticoagulant discovered by Bristol-Myers Squibb. This global
alliance combines Bristol-Myers Squibb's long-standing strengths in
cardiovascular drug development and commercialization with Pfizer’s
global scale and expertise in this field.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information, please visit http://www.bms.com or follow us on
Twitter at http://twitter.com/bmsnews.
About Pfizer Inc.: Working together for a healthier
world™
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a difference for
all who rely on us. To learn more, please visit us at
www.pfizer.com.
Bristol-Myers SquibbMedia:Danielle Halstrom,
609-252-3403danielle.halstrom@bms.comInvestors:Ranya
Dajani, 609-252-5330ranya.dajani@bms.comRyan Asay,
609-252-5020ryan.asay@bms.comorPfizer
Inc.Media:Jennifer Kokell,
212-733-2596jennifer.kokell@pfizer.comInvestors:Ryan
Crowe, 212-733-8160ryan.crowe@pfizer.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2023 to Mar 2024